36476-89-8

Usage

Uses

Used in Pharmaceutical Research:
3-Methanesulfonatoazetidine hydrochloride is utilized as a research tool in pharmaceutical laboratories for studying the function of NNMT. It aids in understanding the enzyme's role in various biological processes and contributes to the development of new drugs that target NNMT.
Used in Drug Development:
3-METHANESULFONATOAZETIDINE HYDROCHLORIDE serves as a crucial starting point for the creation of therapeutic agents that could treat metabolic disorders, cancer, and inflammatory diseases by inhibiting the activity of NNMT. Its use in drug development is aimed at identifying potential drug candidates that can modulate the enzyme's activity effectively and safely.
Used in Metabolic Disorder Treatment Research:
3-Methanesulfonatoazetidine hydrochloride is applied in research focused on the treatment of metabolic disorders. By inhibiting NNMT, it may help regulate the metabolism of nicotinamide, which could have implications for managing such disorders.
Used in Cancer Therapy Research:
In the field of oncology, this hydrochloride salt is used to explore its potential in treating cancer. The inhibition of NNMT may impact cancer cell metabolism and growth, offering a novel approach to cancer therapy.
Used in Inflammatory Disease Research:
3-Methanesulfonatoazetidine hydrochloride is also used in research targeting inflammatory diseases. The modulation of NNMT activity could have anti-inflammatory effects, providing a new avenue for treating such conditions.

Upstream product

• 33301-41-6 1-benzhydryl-3-azetidinyl methanesulfonate 
• 106859-45-4 1-(Diphenylmethyl)-3-azetidinol methanesulfonate (ester) hydrochloride 

Downstream Products

• 136911-53-0 Methanesulfonic acid 1-(4-methyl-benzoyl)-azetidin-3-yl ester 
• 1221161-09-6 C₁₉H₂₂FN₃O₃ 
• 1609019-62-6 C₁₃H₁₇NO₄S 
• 141699-58-3 3-methanesulfonyloxy-azetidine-1-carboxylic acid tert-butyl ester 
• 136911-52-9 1-benzoylazetidin-3-yl methanesulfonate 
• 931410-12-7 1-(4-cyano-4,4-diphenylbutanoyl)azetidin-3-yl methansulfonate 

Relevant academic research and scientific papers

Acylazetine as a dienophile in bioorthogonal inverse electron-demand Diels-Alder ligation

A new bioorthogonal N-acylazetine tag, suitable for tetrazine mediated inverse electron-demand Diels-Alder conjugation, is developed. The tag is small and achiral. We demonstrate the usefulness of N-acylazetine-tetrazine based bioorthogonal chemistry in two-step activity-based protein profiling. The performance of the new tetrazinophile in the labeling of catalytically active proteasome subunits was comparable to that of the more sterically demanding norbornene tag.

CARBOXAMIDE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS

The invention relates to compounds of Formula (I) processes and intermediates for their preparation, their use as muscarinic antagonists and pharmaceutical composition containing them.

Substituted triazole derivatives as oxytocin antagonists

The present invention relates to substituted triazoles of formula (I), uses thereof, processes for the preparation thereof and compositions containing said compounds. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction.

A practical and facile synthesis of azetidine derivatives for oral carbapenem, L-084

An orally active carbapenem L-084, which exhibits high bioavailability in humans, has a 1-(1,3-thiazolin-2-yl)azetidin-3-ylthio moiety at the C-2 position of the 1β-methylcarbapenem skeleton. We established a practical and cost-effective synthesis of 3-mercapto-1-(1,3-thiazolin-2-yl)azetidine (1) for further scale-up production of L-084. This synthesis method entails an industry-oriented reaction of azetidine ring-closure to yield N-benzyl-3-hydroxyazetidine (16), which is eventually converted to 1 via key intermediates, Bunte salts 19 and 20.

Substituted benzoylpiperidine derivatives and their use as Neurokinin antagonists

The present invention provides a compound of the formula:- or a pharmaceutically acceptable acid addition salt thereof, whereinAr is phenyl substituted by 1 or 2 substituent(s) each independently selected from fluoro and chloro;X is NSO2(C1-C4 alkyl), NSO2(halo(C1-C4 alkyl)) or O;m is 0 or 1 ;n is 1 or 2;p is 1 or 2;q is 1 or 2; and r is 1 or 2, together with processes for the preparation of, intermediates used in the preparation of, compositions containing and uses of, such derivatives. The compounds have tachykinin receptor antagonist activity.